Vaping vs Smoking: Is Vaping Really Safer?

Few topics in public health generate more heated debate — and more confident misinformation on both sides — than the safety comparison between vaping and smoking. On one end, you have advocates claiming e-cigarettes are virtually harmless. On the other, you have opponents suggesting they might be just as dangerous as combustible cigarettes. Both positions are wrong.

The truth, as the evidence currently stands, is more nuanced and ultimately more useful: vaping is substantially less harmful than smoking combustible cigarettes, but it is not harmless, and critical questions about long-term effects remain unanswered. That sentence doesn’t fit neatly on a bumper sticker, but it’s what the science actually shows.

Let’s break it apart.

First: The Scale of the Smoking Problem

Before any comparison is meaningful, you need to understand what vaping is being compared against. Combustible cigarettes are, in terms of total mortality, the most dangerous consumer product ever created.

The numbers:

• 480,000 deaths per year in the United States attributable to smoking (CDC)
• More than 8 million deaths per year worldwide (WHO)
• Smoking kills approximately half of all long-term smokers (Doll et al., 2004, BMJ)
• Smoking causes or worsens virtually every organ system: lungs (COPD, lung cancer), heart (heart disease, stroke), blood vessels (peripheral artery disease), immune system (increased infection risk), reproductive system (infertility, pregnancy complications), bones (osteoporosis), eyes (macular degeneration), mouth (oral cancer, gum disease)
• Cigarette smoke contains over 7,000 chemicals, at least 70 of which are proven carcinogens
• Combustion is the primary mechanism of harm — burning organic matter at 600-900 degrees Celsius generates tar, carbon monoxide, polycyclic aromatic hydrocarbons, formaldehyde, benzene, arsenic, cadmium, and dozens of other toxic compounds

This is the baseline. Any harm reduction claim for vaping must be measured against this catastrophic standard.

What’s in Cigarette Smoke vs. E-Cigarette Vapor?

This comparison is the foundation of the harm reduction argument, and the data here is relatively clear.

Cigarette Smoke

Produced by combustion — burning tobacco, paper, and chemical additives at extreme temperatures. Contains:

• Tar — a catch-all term for the particulate matter in smoke; deposits in lungs and airways
• Carbon monoxide — binds to hemoglobin, reducing oxygen delivery
• Formaldehyde, acetaldehyde, acrolein — toxic aldehydes that damage tissue
• Benzene, 1,3-butadiene — known carcinogens
• Polycyclic aromatic hydrocarbons (PAHs) — potent carcinogens
• Heavy metals — arsenic, cadmium, lead
• Hydrogen cyanide — damages cilia in the airways
• Nitrosamines (TSNAs) — tobacco-specific carcinogens
• Radioactive elements (polonium-210, lead-210) — yes, cigarette smoke is mildly radioactive

E-Cigarette Vapor

Produced by heating (not burning) a liquid containing propylene glycol (PG), vegetable glycerin (VG), nicotine, and flavorings to temperatures of approximately 100-250 degrees Celsius. Contains:

• Propylene glycol and vegetable glycerin — generally recognized as safe for ingestion by the FDA, but long-term inhalation effects are not fully characterized
• Nicotine — addictive, cardiovascular effects, but not a primary driver of cancer or lung disease
• Flavoring chemicals — some (particularly diacetyl and related diketones) have known inhalation toxicity, though many manufacturers have removed diacetyl
• Trace levels of aldehydes — formaldehyde, acetaldehyde, and acrolein are present, but at levels typically 95-99% lower than in cigarette smoke under normal use conditions (Goniewicz et al., 2014, Tobacco Control)
• Trace metals — from the heating coil (nickel, chromium, lead); levels vary by device quality and use pattern
• Free radicals — present but at significantly lower levels than in cigarette smoke

The Key Difference: Combustion

The single most important distinction is that e-cigarettes don’t involve combustion. The vast majority of the toxicants in cigarette smoke are produced by burning organic matter. When you eliminate combustion, you eliminate the primary mechanism by which smoking kills.

This doesn’t mean e-cigarette vapor is inert — it contains its own set of potentially harmful substances. But the toxicant profile is categorically different in both composition and magnitude.

The Bottom Line: E-cigarette vapor contains significantly fewer and lower concentrations of toxic chemicals compared to cigarette smoke. The elimination of combustion removes the primary source of carcinogens, carbon monoxide, and tar. However, vapor is not simply “water vapor” — it contains substances whose long-term inhalation effects are not yet fully known.

The 95% Claim: Where It Came From

One of the most widely cited statistics in this debate is the claim that “vaping is 95% safer than smoking.” This figure has been used by governments, health agencies, and vaping advocacy groups worldwide. Here’s its origin and its limitations.

The Source

In 2014, a panel of 12 experts convened by the Independent Scientific Committee on Drugs (ISCD), chaired by Professor David Nutt, used a Multi-Criteria Decision Analysis (MCDA) to rate the harm of 12 nicotine-containing products on 14 different criteria. Their conclusion, published by Nutt et al. (2014) in the European Addiction Research journal, estimated e-cigarettes at approximately 5% of the harm of combustible cigarettes — hence, “95% less harmful.”

In 2015, Public Health England (PHE) published a landmark evidence review (McNeill et al., 2015) that endorsed this estimate, stating: “While vaping may not be 100% safe, most of the chemicals causing smoking-related disease are absent and the chemicals present pose limited danger.”

The Limitations

The 95% figure has been critiqued on several grounds:

1. Expert opinion, not measurement. The MCDA was based on expert judgment, not direct epidemiological comparison. No study has measured the actual long-term mortality of vapers vs. smokers because vaping hasn’t existed long enough.

2. Short-term data only. At the time of the estimate, e-cigarettes had only been widely available for about 7-8 years. Smoking-related diseases (cancer, COPD) take 20-40 years to develop. We cannot know the 30-year cancer risk of vaping based on 8 years of data.

3. Product heterogeneity. “E-cigarettes” is not a monolithic category. A regulated, pharmaceutical-grade device with controlled nicotine delivery is different from a modified high-wattage device with unknown liquids. The 95% estimate applies to a general category that contains enormous variation.

4. Conflicts of interest. Some members of the expert panel had financial ties to the vaping industry, though the PHE report was conducted independently.

Where the Science Stands Now

Most major health organizations agree that vaping is substantially less harmful than smoking but avoid endorsing a specific percentage:

• Public Health England / UK Health Security Agency (2022 update): “Vaping poses only a small fraction of the risks of smoking”
• National Academies of Sciences, Engineering, and Medicine (NASEM, 2018): “There is conclusive evidence that completely substituting e-cigarettes for combustible tobacco cigarettes reduces users’ exposure to numerous toxicants and carcinogens”
• American Cancer Society (2019): “Based on currently available evidence, using current generation e-cigarettes is less harmful than smoking cigarettes, but the health effects of long-term use are not yet known”
• WHO (2021): More cautious; acknowledges reduced exposure to toxicants but emphasizes that e-cigarettes are “undoubtedly harmful” and warns against endorsing them as a cessation tool without more evidence

Known Risks of Vaping

While significantly less harmful than smoking, vaping is not without documented risks.

Nicotine Dependence

E-cigarettes deliver nicotine, and nicotine is addictive. Modern pod-based systems (like JUUL and similar devices) deliver nicotine efficiently enough to produce full physical dependence. Nicotine itself, while not a primary driver of cancer, has documented effects:

• Cardiovascular: Acutely raises heart rate and blood pressure; chronic effects under study
• Developmental: Harmful to adolescent brain development (prefrontal cortex maturation continues until approximately age 25)
• Pregnancy: Associated with adverse fetal outcomes
• Addiction: Creates physical dependence requiring ongoing use

EVALI (E-Cigarette or Vaping Product Use-Associated Lung Injury)

In 2019, a sudden outbreak of severe lung injuries associated with vaping alarmed the US. At its peak:

• 2,807 hospitalized cases and 68 deaths were reported to the CDC
• Investigation identified vitamin E acetate — a thickening agent used in black market THC cartridges — as the primary cause
• The outbreak was overwhelmingly linked to illicit, unregulated THC vape products, not commercial nicotine e-cigarettes
• Cases dropped dramatically once public health warnings were issued about illicit THC products

The EVALI outbreak is often used to argue that vaping is dangerous, but the key context is critical: the lung injuries were caused by a specific adulterant in illegal THC products, not by nicotine vaping. However, the episode demonstrated the risks of unregulated products and the potential for unknown additives to cause acute harm.

Respiratory Effects

Studies on the respiratory effects of vaping show mixed results:

• Short-term: Some evidence of airway inflammation, increased airway resistance, and altered immune cell function in the lungs (Madison et al., 2019, Journal of Clinical Investigation)
• In vitro studies: E-cigarette vapor/aerosol exposures show toxicity to lung cells, though consistently less than cigarette smoke exposure
• Clinical studies: Smokers who switch completely to vaping show improvements in respiratory symptoms, lung function, and airway inflammation (Polosa et al., 2016, Internal and Emergency Medicine)
• Long-term: Unknown. The critical question — does 20-30 years of daily vaping cause COPD, lung cancer, or other chronic disease? — cannot yet be answered because the exposure period hasn’t been long enough

Cardiovascular Effects

• Nicotine acutely raises heart rate and blood pressure regardless of delivery method
• Some studies suggest e-cigarette use increases arterial stiffness and endothelial dysfunction, though to a lesser degree than smoking
• The long-term cardiovascular impact of daily vaping is not yet established
• A key uncertainty: smoking’s cardiovascular harm comes partly from carbon monoxide, oxidative stress from combustion products, and chronic inflammation — all of which are reduced or absent in vaping. Whether the remaining nicotine-mediated cardiovascular effects are clinically significant long-term is an open question.

Flavoring Concerns

• Diacetyl and related compounds (2,3-pentanedione, acetoin) can cause bronchiolitis obliterans (“popcorn lung”) when inhaled in high concentrations. Many manufacturers have removed diacetyl, but not all, and not in all markets.
• Cinnamon aldehyde (cinnamaldehyde) has shown cytotoxicity in in vitro studies
• The FDA’s “generally recognized as safe” (GRAS) designation for flavoring chemicals applies to ingestion, not inhalation — the lungs and the digestive system process substances very differently

What This Means For You: Vaping carries real risks — nicotine addiction, potential respiratory and cardiovascular effects, exposure to certain chemicals, and unknown long-term consequences. These risks are substantially lower than smoking, but they are not zero. For a non-smoker, the risk-benefit calculation is simple: don’t start. For a current smoker unable to quit by other means, the calculus is different.

Vaping vs smoking safety comparison — Sources: Public Health England, 2022; NASEM, 2018; CDC

The Dual Use Problem

Here’s the part of the conversation that often gets lost: many people who vape also continue to smoke. This is called dual use, and it’s more common than complete switching.

Research from the Population Assessment of Tobacco and Health (PATH) Study found that a substantial proportion of vapers are dual users — smoking and vaping simultaneously. The health implications are significant:

• Dual use provides little to no health benefit over smoking alone. Studies by Shahab et al. (2017) in Annals of Internal Medicine found that dual users had biomarker levels (NNAL, a carcinogen metabolite) similar to exclusive smokers, while exclusive vapers had levels dramatically lower.
• The harm reduction potential of vaping is only realized through complete substitution — replacing every cigarette with vaping, not adding vaping on top of continued smoking.
• Even a few cigarettes per day produce disproportionate harm — the dose-response curve for cardiovascular risk from smoking is steep at low levels. Research suggests there’s no safe level of cigarette smoking.

The Bottom Line: If you smoke and vape, you’re getting most of the harm of smoking with the added nicotine of vaping. The harm reduction argument only applies if you switch completely. Even 1-2 cigarettes per day alongside vaping largely negates the potential benefit.

The Gateway Debate: Does Vaping Lead to Smoking?

This is one of the most contentious questions in tobacco control, and it’s relevant primarily for youth.

The Concern

Multiple studies have found an association between adolescent vaping and subsequent smoking initiation. A meta-analysis by Soneji et al. (2017) in JAMA Pediatrics found that e-cigarette use among youth was associated with approximately 3.5 times higher odds of subsequent cigarette smoking.

The Counterarguments

• Correlation vs. causation. Youth who try e-cigarettes may be the same risk-taking population who would have tried cigarettes anyway (the “common liability” hypothesis). Some researchers argue that vaping isn’t causing smoking — it’s that the same adolescents prone to trying one are prone to trying the other.
• Population-level trends. In countries and periods where youth vaping has increased, youth smoking rates have continued to decline — and in many cases, have declined faster than before e-cigarettes were available. US youth smoking rates fell from 15.8% in 2011 to 2.3% in 2022 (CDC Youth Risk Behavior Survey), even as vaping surged.
• Experimentation vs. regular use. Many studies count “ever tried” as use. The majority of adolescents who experiment with vaping do not progress to regular use of any nicotine product.

The Current Consensus

There is no settled consensus. Most researchers agree that:

• Youth should not use any nicotine product
• Any gateway effect, if it exists, appears to be modest at the population level
• The decline in youth smoking has not been reversed by the rise of vaping
• Preventing youth vaping initiation is important regardless of the gateway question, because nicotine dependence during adolescence has its own developmental consequences

Harm Reduction vs. Precautionary Principle

The vaping debate fundamentally pits two legitimate public health philosophies against each other.

The Harm Reduction Position (UK, New Zealand, Canada)

• Smokers who cannot or will not quit nicotine entirely should be encouraged to switch to the least harmful delivery system available
• The known, catastrophic harms of smoking vastly outweigh the uncertain, likely smaller harms of vaping
• Waiting for perfect evidence while millions die from smoking is itself a form of harm
• E-cigarettes should be regulated, not prohibited
• The UK has embraced this position most fully, with the NHS actively prescribing e-cigarettes as a cessation aid

The Precautionary Position (WHO, many US health organizations)

• We should not endorse a product with unknown long-term effects
• The tobacco industry has a long history of deception about product safety
• Youth nicotine addiction is a serious concern
• Other proven cessation tools exist (NRT, varenicline, bupropion, counseling)
• E-cigarettes should not be recommended as a first-line cessation tool until more evidence is available

What the Evidence Supports

Both positions have legitimate grounding. The strongest evidence-based statement would be:

For current smokers: Switching completely to regulated e-cigarettes is very likely to substantially reduce health risk. The magnitude of that reduction is debated, but the direction is not. E-cigarettes can be considered as a cessation or harm reduction tool, particularly for smokers who have failed with other methods.

For non-smokers and youth: There is no health benefit to starting to vape. The risks — nicotine addiction, potential respiratory effects, unknown long-term consequences — are all downside with no upside.

For everyone: The ideal outcome is neither smoking nor vaping. Complete cessation of all nicotine products eliminates all associated risks.

E-Cigarettes as a Cessation Tool: What Does the Evidence Say?

A Cochrane Review by Hartmann-Boyce et al. (2022) examined the evidence for e-cigarettes as cessation aids:

• E-cigarettes with nicotine vs. NRT: Higher quit rates with e-cigarettes (relative risk 1.53; moderate certainty evidence)
• E-cigarettes with nicotine vs. behavioral support alone: Higher quit rates with e-cigarettes
• Absolute quit rates at 6+ months: Approximately 9-14% in the e-cigarette groups vs. 6-10% for NRT comparators

A landmark randomized controlled trial by Hajek et al. (2019) published in the New England Journal of Medicine found that e-cigarettes were nearly twice as effective as NRT for smoking cessation at 1 year (18% vs. 9.9%). However, 80% of successful quitters in the e-cigarette group were still vaping at the 1-year mark, raising questions about whether they’ve traded one nicotine dependency for another — albeit a less harmful one.

Practical Guidance Based on Current Evidence

If You Currently Smoke

1. First-line approach: Evidence-based cessation methods (varenicline, combination NRT, bupropion + behavioral counseling) have the strongest evidence and lead to complete nicotine cessation
2. If those haven’t worked: Switching completely to a regulated e-cigarette is likely to substantially reduce your health risk compared to continued smoking
3. Don’t dual use. If you switch, switch completely. Cutting down cigarettes while vaping provides minimal benefit.
4. Consider vaping as a bridge, not a destination. The best outcome is eventually quitting vaping too. Many people step down their nicotine concentration over time and eventually stop.

If You Currently Vape (Never Smoked)

1. You are exposing yourself to nicotine dependence and inhaled chemicals with no offsetting benefit
2. Quitting vaping eliminates these risks entirely
3. Nicotine withdrawal from vaping follows a similar timeline to cigarette withdrawal — the same strategies and medications can help

If You’re Considering Starting

Don’t. Whether it’s cigarettes or e-cigarettes, the introduction of nicotine dependence adds risk with no health benefit. The safest option is never starting.

What We Don’t Know Yet

Scientific honesty requires acknowledging the significant gaps in our knowledge:

• 30-year cancer risk: We have no long-term epidemiological data on vaping and cancer. Cigarettes took 30-50 years of widespread use before the lung cancer link was definitively established. We’re only about 15 years into the e-cigarette era.
• COPD risk: Whether chronic inhalation of PG/VG aerosol damages lung tissue over decades is unknown.
• Cardiovascular long-term effects: The chronic impact of daily nicotine inhalation via e-cigarettes on heart disease risk requires more study.
• Reproductive effects: Limited data on the impact of vaping on fertility, pregnancy outcomes, and fetal development.
• Product evolution: E-cigarettes are evolving rapidly. Today’s products are different from those studied 5 years ago. Research on older devices may not apply to current ones, and vice versa.

The honest answer to “Is vaping safe?” is: Safer than smoking, yes. Safe in absolute terms? We don’t know yet. And anyone who tells you they know the answer with certainty in either direction is outrunning the evidence.

Sources and Further Reading

• Nutt, D.J., et al. (2014). “Estimating the harms of nicotine-containing products using the MCDA approach.” European Addiction Research, 20(5), 218-225.
• McNeill, A., et al. (2015). “E-cigarettes: an evidence update.” Public Health England.
• McNeill, A., et al. (2022). “Nicotine vaping in England: an evidence update including health risks and perceptions.” UK Health Security Agency.
• National Academies of Sciences, Engineering, and Medicine. (2018). Public Health Consequences of E-Cigarettes. National Academies Press.
• Goniewicz, M.L., et al. (2014). “Levels of selected carcinogens and toxicants in vapour from electronic cigarettes.” Tobacco Control, 23(2), 133-139.
• Hajek, P., et al. (2019). “A randomized trial of e-cigarettes versus nicotine-replacement therapy.” New England Journal of Medicine, 380(7), 629-637.
• Hartmann-Boyce, J., et al. (2022). “Electronic cigarettes for smoking cessation.” Cochrane Database of Systematic Reviews, 11, CD010216.
• Shahab, L., et al. (2017). “Nicotine, carcinogen, and toxin exposure in long-term e-cigarette and nicotine replacement therapy users.” Annals of Internal Medicine, 166(6), 390-400.
• Soneji, S., et al. (2017). “Association between initial use of e-cigarettes and subsequent cigarette smoking among adolescents and young adults.” JAMA Pediatrics, 171(8), 788-797.
• Madison, M.C., et al. (2019). “Electronic cigarettes disrupt lung lipid homeostasis and innate immunity.” Journal of Clinical Investigation, 129(10), 4290-4304.
• Polosa, R., et al. (2016). “Health effects in COPD smokers who switch to electronic cigarettes.” Internal and Emergency Medicine, 11(4), 575-585.
• Doll, R., et al. (2004). “Mortality in relation to smoking: 50 years’ observations.” BMJ, 328(7455), 1519.
• Centers for Disease Control and Prevention. “Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping.”
• Centers for Disease Control and Prevention. “Smoking & Tobacco Use: Fast Facts.”
• World Health Organization. “Tobacco: E-cigarettes.”